Genesis and Lilly Ink AI Collab Worth Up to $670M

Genesis Therapeutics and Eli Lilly have entered into a strategic collaboration to discover novel therapies utilizing Genesis’ AI platform.

Under the agreement, Genesis will partner with Lilly on three initial targets and receive an upfront payment of $20 million.